Seroquel Poised To Take Market Lead Within Months – AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca expects Seroquel to surpass Johnson & Johnson's Risperdal in terms of prescription share within the antipsychotic market by the end of the year
You may also be interested in...
Seroquel 12-Week Data Is Longest In Class For Acute Bipolar Disorder Monotherapy
The efficacy of AstraZeneca’s quetiapine was established in two 12-week monotherapy trials, revised labeling states. Seroquel’s original bipolar indication was based upon three-week trial data.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.